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Abstract
Fracture risk in type 2 diabetes is increased despite normal or high bone mineral density, implicating poor bone quality as a
risk factor. Raloxifene improves bone material and mechanical properties independent of bone mineral density. This study
aimed to determine if raloxifene prevents the negative effects of diabetes on skeletal fragility in diabetes-prone rats. Adult
Zucker Diabetic Sprague-Dawley (ZDSD) female rats (20-week-old, n = 24) were fed a diabetogenic high-fat diet and were
randomized to receive daily subcutaneous injections of raloxifene or vehicle for 12 weeks. Blood glucose was measured
weekly and glycated hemoglobin was measured at baseline and 12 weeks. At sacrifice, femora and lumbar vertebrae were
harvested for imaging and mechanical testing. Raloxifene-treated rats had a lower incidence of type 2 diabetes compared
with vehicle-treated rats. In addition, raloxifene-treated rats had blood glucose levels significantly lower than both diabetic
vehicle-treated rats as well as vehicle-treated rats that did not become diabetic. Femoral toughness was greater in
raloxifene-treated rats compared with both diabetic and non-diabetic vehicle-treated ZDSD rats, due to greater energy
absorption in the post-yield region of the stress-strain curve. Similar differences between groups were observed for the
structural (extrinsic) mechanical properties of energy-to-failure, post-yield energy-to-failure, and post-yield displacement.
These results show that raloxifene is beneficial in preventing the onset of diabetes and improving bone material properties
in the diabetes-prone ZDSD rat. This presents unique therapeutic potential for raloxifene in preserving bone quality in
diabetes as well as in diabetes prevention, if these results can be supported by future experimental and clinical studies.
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Introduction
People with type 2 diabetes mellitus have a greater risk for bone
fragility fractures compared with healthy adults, despite normal or
higher bone mineral density [1–5]. This suggests that bone quality,
not quantity, is responsible for the increase in fracture risk in
diabetes. Raloxifene is a selective estrogen receptor modulator
(SERM) used clinically in women to treat post-menopausal
osteoporosis. Our group has previously shown that dogs treated
with raloxifene have greater femoral and vertebral toughness,
despite no significant effect on bone mineral density [6,7].
Similarly, in post-menopausal women, raloxifene decreases risk
of fracture with little effect on bone mineral density [8–10]. This
indicates that raloxifene improves bone resistance to fracture by
affecting bone quality, and may therefore be an agent with
potential to improve bone properties in diabetes where fracture
risk is higher apparently due to reduced bone quality rather than
reduced bone mass.
The Zucker Diabetic Sprague-Dawley (ZDSD) rat is a recently
developed rodent model of type 2 diabetes crossbred from the diet-
induced-obesity CD (Sprague-Dawley-derived) and lean Zucker
Diabetic Fatty rats (ZDFfa/+) [11]. Unlike the diabetic obese
ZDFfa/fa rats, ZDSD rats do not have a leptin receptor mutation,
and both sexes develop a type 2 diabetes phenotype of polygenic
origin more gradually with age or by induction with a high-fat diet,
thus reflecting more closely the pathogenesis of human type 2
diabetes [11,12]. This study aimed to test the effects of raloxifene
on bone quality and strength in adult female ZDSD rats. Although
we have shown positive effects of raloxifene on bone material
properties in normoglycemic animals, no studies have been
performed in a model subject to diabetes to determine whether
raloxifene in a hyperglycemic environment will prevent increased
skeletal fragility.
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Materials and Methods
Animals and Experimental Design
Twenty-week-old female (n = 24) Zucker Diabetic Sprague
Dawley (ZDSD) rats (PreClinOmics, Indianapolis, IN) were
randomized (n = 12/group) to receive daily subcutaneous injec-
tions of raloxifene (0.5 mg/kg, Eli Lilly Co., Indianapolis, IN) or
vehicle (10% cyclodextrin, Sigma-Aldrich) for 12 weeks, and all
rats were fed a diabetogenic high-fat diet (48% fat; 5SCA,
TestDiet, Richmond, IN) for the duration of the study. The high-
fat diet is used to synchronize diabetes induction. Additionally, in
contrast to male ZDSD rats that will develop diabetes with age
even while on a normal rat diet[11], female ZDSD rats are more
resistant to developing diabetes and require the high-fat diet for
diabetes induction and to maintain the diabetic state. Blood
glucose was measured weekly by glucometer (AlphaTRAK,
Abbott Laboratories, Abbott Park, IL) and diabetes was defined
as blood glucose $ 250 mg/dL for 2 consecutive weeks. Whole
blood and serum samples were collected at baseline and sacrifice.
Glycated hemoglobin (HbA1c,%) was measured in whole blood by
immunological assay (Daytona Chemistry Anlayzer, Randox
Laboratories, Kearneysville, WV). Serum insulin was measured
by ELISA (Mercodia Inc., Winston Salem, NC) and serum
triglycerides were measured by colorimetric assays (Daytona
Chemistry Analyzer, Randox Laboratories, Kearneysville, WV).
Serum c-telopeptide of type I collagen was measured by ELISA
(Biotang Inc., Lexington, MA). Prior to sacrifice, rats were double-
labeled by intraperitoneal injections of calcein (5 mg/kg; Sigma-
Alrich, St. Louis, MO) with a 7-day interlabel period and a 3-day
period for incorporation and washout (i.e. 1-7-1-3). Bones (femora,
lumbar vertebrae) were collected at the time of sacrifice when rats
were 32-weeks-old. Femora and L4 vertebrae were wrapped in
saline-soaked gauze and frozen at 220uC for storage prior to bone
imaging and mechanical testing; L5 vertebrae were cleaned of soft
tissue and fixed in 10% phosphate-buffered formalin for 48 h, then
transferred to 70% ethanol, dehydrated in a graded series of
ethanol from 70–100%, then embedded (undecalcified and
unstained) in methyl-methacrylate with 3% dibutyl phthalate
(Sigma-Aldrich, St. Louis, MO) for dynamic histomorphometry.
This protocol was approved by the Indiana University Animal
Care and Use Committee, and all institutional and national
guidelines for the care and use of laboratory animals were
followed.
Bone Imaging
Dual-energy x-ray absorptiometry (DXA, GE Lunar PixiMus,
Madison, WI) was performed on excised right femora and L4
vertebrae for measures of areal bone mineral density (aBMD g/
cm2), bone mineral content (BMC, g) and area (cm2). Peripheral
quantitative computed tomography (pQCT, XCT Research SA+,
Stratec Medizintechnik GmbH, Pforzheim, Germany) was
performed on the right femur midshaft for cortical bone
morphometric properties (volumetric BMD (vBMD), BMC,
cortical area and thickness, periostal and endosteal circumferences
and x-axis cross-sectional moment of inertia). Micro-computed
tomography (mCT, Brucker Skyscan 1172, Kontich, Belgium) was
performed on L4 vertebral bodies and the right distal femur for
cancellous bone morphometric properties. Scans were done at
8 mm resolution, 65 kV and 120 mA using a 0.7u rotation step.
Reconstructed mCT images (NRecon software) were analyzed
using CT Analyzer software (Skyscan, Kontich, Belgium). The
same parameters/thresholds were used for each site for recon-
struction and analysis. Outcome measurements included whole
vertebral body bone volume (BV, mm3), trabecular bone volume
fraction (BV/TV,% [where TV is tissue volume]), trabecular
number (Tb.N, mm21), trabecular thickness (Tb.Th, mm),
trabecular separation (Tb.Sp, mm), connectivity density (Conn.D,
mm23), and structural model index (SMI).
Mechanical Testing
Mechanical properties of the femur mid-diaphysis were
determined by three-point bending using standard methods [13].
Briefly, bones were thawed to room temperature, and placed
posterior side down on the bottom support (18 mm wide) of a
servohydraulic test system (100P225 Modular Test Machine,
TestResources, Shakopee, MN), so that the descending probe
contacted the central anterior surface. Bones were loaded to failure
using a displacement rate of 2 mm/min. Force vs. displacement
data was collected at 10 Hz. Material properties were calculated
based on standard equations using structural mechanical proper-
ties and geometric measures from pQCT [13]. Reduced platen
compression (RPC) was used to determine mechanical properties
of cancellous bone on a 2 mm thick slab of distal femur (100P225
Modular Test Machine, TestResources, Shakopee, MN). For
RPC, platen size was set at 70% of the maximum circle diameter
to include only cancellous bone [6], which was determined by
uCT scanning of the samples prior to mechanical testing. Tests
were performed at 0.5 mm/min and data collected at 2 Hz until
sample failure.
Mechanical properties of L4 vertebrae were determined by axial
compression after removal of vertebral processes using a dremel
tool with a minisaw attachment, and removal of the cranial and
caudal endplates parallel to each other using a low-speed bone saw
(Isomet, Buehler, Lake Bluff, IL). L4 vertebral bodies (+/- 3.5 mm
height) were loaded at a rate of 0.5 mm/min until failure
(100P225 Modular Test Machine) and data were collected at
10 Hz.
Structural mechanical properties of femoral cortical bone, L4
vertebrae and cancellous bone from the RPC testing were
determined from the load-deformation curves using standard
definitions. Material properties were calculated based on standard
equations using structural mechanical properties and geometric
measures from caliper measurements and pQCT (cortical bone) or
mCT [13].
Bone Turnover
Bone turnover was measured by serum C-terminal telopeptides
of type I collagen (Ctx) by EIA (RatLaps
TM
, IDS, Inc.), and by
dynamic histomorphometry of L5 vertebrae. Thin sections
(approximately 6 mm) of the L5 vertebra were cut longitudinally
with a microtome (Reichert-Jung SuperCut). Approximately
5 mm2 of cancellous bone tissue 0.5 mm from the endocortical
surface was analyzed from one section. Measurements were made
at 200x magnification using a fluorescent microscope (Nikon
Optiophot 2, Nikon, Inc., Garden City, NY) and images were
analyzed using the Bioquant system (R&M Biometrics, Nashville,
TN). All measurements and calculations were performed following
the guidelines of the American Society for Bone and Mineral
Research Histomorphometry Nomenclature Committee [14].
Parameters measured included single-label perimeter (sL.Pm),
double-label perimeter (dL.Pm), and interlabel width (Ir.L.Wi).
From these primary measurements, the following outcome
parameters were calculated: mineral apposition rate (MAR =
Ir.L.Wi/7 days [mm/day]); mineralizing surface (MS/BS =
(0.5*sL.Pm + dl.Pm)/B.Pm*100 [%]); and bone formation rate
(BFR/BS = MAR*MS/BS*365 [mm3/mm2/year]).
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Statistical analyses
The planned two-way analysis of variance (diabetes and
raloxifene as factors) was not possible because none of the
raloxifene-treated rats became diabetic. Thus, one-way analysis of
variance with Tukey’s posthoc analysis was used to detect
differences in means among the three groups: raloxifene-treated
(RAL), vehicle-treated non-diabetic (VEH-ND), and vehicle-
treated diabetic rats (VEH-D). Body weight was tested as a
covariate for all measures and used for DXA variables and L4
BV/TV. Diabetes induction was analyzed by log-rank test of
Kaplan-Meier survival curves and Fisher’s exact tests. Statistical
analyses were performed using SAS 9.2 software (Cary, NC) and
significance was set at a 0.05. Values are presented as least squares
means 6 SEM unless otherwise noted.
Results
Rats randomized to receive raloxifene injections and vehicle
injections had similar baseline body weight (mean 6 SD: 342614
and 348623 g, respectively), blood glucose (mean 6 SD: 11467
and 112612 mg/dL, respectively), HbA1c (mean 6 SD: 4.560.3
[n = 11] and 4.560.1% [n=9], respectively), serum insulin (mean
6 SD: 0.5060.26 [n= 6] and 0.4760.36 [n= 10], respectively)
and serum triglycerides (mean 6 SD: 3.3761.39 [n= 7] and
2.7361.01 [n= 9]). After 12 weeks, none of the 12 rats treated
with raloxifene became diabetic whereas 4 out of 12 rats that
received vehicle injections became diabetic. By Fisher’s exact test,
the difference in diabetes frequency did not reach statistical
significance (p = 0.09). However, by survival analysis of Kaplan-
Meier curves, raloxifene significantly reduced diabetes induction
(p = 0.03) (Fig. 1a).
At the time of sacrifice, vehicle-treated non-diabetic (VEH-ND)
rats weighed more than both vehicle-treated diabetic (VEH-D)
(p,0.0001) and raloxifene-treated (RAL) (p,0.0001) rats (Ta-
ble 1).VEH-D rats had higher blood glucose over the course of
the study, as determined by area-under-the-curve (AUC) com-
pared with RAL or VEH-ND rats (p,0.0001) (Fig. 1b,c).
Additionally, RAL-treated rats had lower cumulative blood
glucose over the course of the study (AUC) than VEH-ND rats
(p = 0.048) (Fig. 1c), but endpoint values were not significantly
different between RAL-treated and VEH-ND rats (Table 1). At
sacrifice, HbA1c was higher in VEH-D (p,0.0001) compared
with RAL and VEH-ND rats. Serum insulin tended to be lower in
the VEH-D rats compared with the VEH-ND and RAL-treated
rats, but this was not significant. Serum triglycerides were higher
in VEH-D rats compared with the RAL-treated rats (p = 0.02)
(Table 1). Bone resorption measured bv serum Ctx was similar
among VEH-ND, VEH-D, and RAL-treated rats. However,
dynamic histomorphometry showed non-significant trends for
lower MS/BS (228%) and BFR/BS (226%) but higher MAR (+
10%) in RAL-treated rats versus VEH-ND rats. Additionally,
diabetic rats (VEH-D) had significantly lower MAR and non-
significant trends for lower MS/BS and BFR/BS compared to the
non-diabetic animals (VEH-ND or RAL-treated) (Table 1).
Areal bone mineral density and bone mineral content of the
whole femur were lower in VEH-D compared with the other two
groups (Table 2). There were no significant differences among
groups for pQCT measures of the femoral midshaft. In the distal
femur, bone volume normalized to tissue volume, trabecular
thickness, and trabecular number were lower, and trabecular
separation was higher in VEH-D rats compared with the other
two groups, and structure model index was higher (more rod-like)
in VEH-D compared with RAL rats (Table 2). There were no
significant differences among groups for DXA or mCT measures of
L4 vertebrae (Table 2).
RAL-treated rats had greater energy to failure and post-yield
energy to failure in femoral cortical bone compared with VEH-
ND and VEH-D rats (Table 3). Correspondingly, the material-
level properties of femoral toughness and post-yield toughness
were also higher in RAL-treated rats (Table 3). There were no
differences among groups in structure-level or material-level
mechanical properties from vertebral axial compression (Ta-
ble 3). RPC of the distal femur cancellous bone revealed greater
energy to ultimate force in RAL versus VEH-D rats, and non-
significant trends for greater toughness in RAL rats versus VEH-
ND (p= 0.07) and VEH-D (p= 0.06) rats. Ultimate stress was
significantly greater in RAL rats compared with VEH-D rats
(Table 3). VEH-D rats had lower ultimate force and stiffness
compared with RAL and VEH-ND, but the corresponding
material property of modulus was not different among groups.
Discussion
This study showed that raloxifene treatment in female ZDSD
rats improved blood glucose levels and showed a trend for
prevention of type 2 diabetes while imparting a beneficial effect on
bone material properties. While the frequency of diabetes between
vehicle and raloxifene treated animals was not statistically different
by Fisher’s exact test, there was a significant difference by survival
analysis using Kaplan-Meier curves. This is not conclusive but at
least suggestive of a benefit of raloxifene for prevention of diabetes.
The finding that raloxifene might prevent the onset of type 2
diabetes in ZDSD rats was an unexpected outcome of this study. A
randomized controlled trial [15] found that raloxifene did not
improve insulin sensitivity or glycemic control in postmenopausal
women who had type 2 diabetes, and a post-hoc analysis [16] of
the Multiple Outcomes of Raloxifene Evaluation (MORE) trial
found no effect of raloxifene on glycemic control in postmeno-
pausal women with or without diabetes, although a beneficial
effect was found on serum lipids. However, these two studies did
not evaluate the effect of raloxifene on diabetes onset. Conversely,
our results are supported by experimental evidence on the effect of
raloxifene on glucose homeostasis and diabetes: it has been shown
that estradiol prevents pancreatic b-cell failure in diabetic rats fed
a high-fat diet by suppressing fatty acid synthesis and accumula-
tion within the b-cells through estrogen receptor signaling [17],
and the same research group found similar results with raloxifene
in an in vitro study [18]. Therefore, a potential mechanism by
which raloxifene could prevent the onset or slow the progression of
diabetes is by preventing pancreatic b-cell failure. Additionally,
two recent clinical studies [19,20] found a beneficial effect of
raloxifene on serum lipids in women with type 2 diabetes, further
supporting a role beyond bone for raloxifene to improve health in
people with diabetes.
The fact that none of the raloxifene treated animals became
diabetic, while an interesting outcome in itself, was a limitation of
this study as it precluded our ability to analyze the effects of
raloxifene on bone in rats with established diabetes. However, we
were able to show a benefit of raloxifene on bone toughness in a
diabetes-prone rat model. While we have previously reported a
positive effect of raloxifene on bone toughness in non-diabetic
canines [6,7], this effect has not been previously shown in bones of
normal rats [21,22]. It is possible the predisposition to diabetes in
the ZDSD rats creates a therapeutic window for an effect of
raloxifene on bone toughness that is not present in normal rats.
Another possible limitation of our study is that we did not
include a ZDSD group on a normal diet. However, this would not
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Figure 1. Diabetes Incidence and Glucose Levels in Raloxifene and Vehicle-Treated Rats. Panel A) Female ZDSD rats treated with
raloxifene (RAL) had lower incidence of diabetes compared with vehicle treated rats (VEH) by survival analysis (p = 0.03) (shown), but by Fisher’s exact
test, the frequency of diabetes in VEH and RAL treated rats did not reach statistical significance (p = 0.09). Panels B,C) Over the course of the study,
blood glucose was lowest in raloxifene treated rats (RAL), and highest in vehicle-injected rats that became diabetic (VEH-D), as assessed by area-
under-the-curve (AUC). Different letters indicate differences in means with p,0.05.
doi:10.1371/journal.pone.0108262.g001
Table 1. Body weight, metabolic parameters and bone turnover at end of studya.
VEH-ND (n=8) VEH-D (n=4)b RAL (n =12)
Body weight, g 532.5 (10.9) a 411.0 (15.4) b 417.8 (8.9) b
Serum glucose, mg/dL 163.8 (8.0) a 472.3 (11.3) b 138.9 (6.5) a
Blood HbA1c,% 4.8 (0.2) a 10.3 (0.2) b 4.7 (0.1) a
Serum triglycerides, mg/dL 5.7 (0.7) ab 7.7 (1.0) a 4.4 (0.6) b
Serum insulin, mg/L 3.6 (0.6) a 1.8 (0.9) a 3.2 (0.5) a
Serum Ctx, ng/mL 19.6 (5.0) a 34.9 (7.0) a 23.9 (4.1) a
L5 Histomorphometry
MAR, mm/day 1.03 (0.11) a 0.43 (0.18) b 1.13 (0.10) a
MS/BS,% 4.60 (0.85) a 1.07 (1.39) a 3.33 (0.76) a
BFR/BS, mm3/mm2/year 18.27 (3.78) a 2.13 (6.18) a 13.52 (3.38) a
aDifferent letters in each row indicate differences among groups by Tukey’s post-hoc comparisons, p,0.05.
bn = 3 for VEH-D for the L5 histomophometry measures due to unavailable sample from 1 rat.
doi:10.1371/journal.pone.0108262.t001
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have been a true control for the diabetes-prone rats because the
effects of the different dietary composition on bone’s material
properties are not known. Moreover, we did not use CD rats
which are sometimes used as non-diabetic controls. CD rats are
not prone to diabetes even on a high fat diet, but are prone to
obesity, and would introduce additional weight-related variables
that could affect BMD or other mechanical properties of bone.
The effect of raloxifene on bone toughness was significant only
for the femur, representing an effect on cortical bone, but a near-
significant trend for greater toughness with raloxifene treatment
was also observed for the distal femur by RPC, indicating a
possible effect on cancellous bone as well. Our previous canine
studies showed a beneficial effect of raloxifene on toughness in
both cortical and cancellous bone [6,7]. Because cortical bone
turnover is relatively slow [23], the effect of raloxifene on cortical
bone toughness implies a direct effect of raloxifene on the existing
bone material, rather than on newly formed bone. Furthermore,
intracortical remodeling does not normally occur in rats and does
not occur in the ZDSD rats. One mechanism by which raloxifene
may improve toughness is by altering the hydration of the bone.
We have shown that bone beams carved from human and dog
cortical bone, when soaked in a raloxifene solution, have greater
toughness and that this is associated with higher water content of
the bone [24]. Greater toughness and hydration were also
observed in cortical bone beams from dogs treated in vivo with
raloxifene for 1 year [24].
Additionally, our previous canine study showed no effect of
raloxifene on BMD, which corresponds to clinical data from
raloxifene trials in which fracture risk is reduced with little change
in BMD [8210]. Similarly, in the present study of diabetes-prone
ZDSD rats, treatment with raloxifene resulted in greater femoral
toughness without an effect on BMD, suggesting that raloxifene
affects bone strength by improving bone quality rather than
quantity. Because people with type 2 diabetes often have normal
or high bone mineral density, the increased fracture risk observed
in these patients appears to be due to impaired bone quality rather
than reduced bone quantity. However, in this study, diabetic rats
actually had lower bone density and mass compared with non-
diabetic rats. This difference between human type 2 diabetes and
the ZDSD rat model might be explained as follows: in humans
with type 2 diabetes, overweight and obesity often persist after the
onset of diabetes, and excess body weight may be protective of
bone mass through mechanical loading or the positive effects of
leptin and estrogen produced by adipose tissue. Conversely,
Table 2. Bone mass and microarcitecture of the femur and L4 vertebra from female ZDSD ratsa.
VEH-ND (n=8) VEH-D (n=4) RAL (n=12)
Total Femur DXA
aBMD, g/cm2 0.249 (0.005) a 0.224 (0.004) b 0.246 (0.003) a
BMC, g 0.626 (0.010) a 0.574 (0.009) b 0.619 (0.006) a
Area, cm2 2.51 (0.03) a 2.56 (0.03) a 2.51 (0.02) a
Midshaft femur pQCT
Ct. vBMD, mg/cm3 1473 (2) a 1467 (3) a 1475 (2) a
Ct. BMC, mg/mm 10.2 (0.1) a 10.1 (0.1) a 10.2 (0.1) a
Ct.Ar, mm3 6.90 (0.06) a 6.89 (0.08) a 6.90 (0.05) a
Ct.Th, mm 0.86 (0.01) a 0.85 (0.01) a 0.85 (0.01) a
Periosteal Circumference, mm 10.7 (0.08) a 10.9 (0.11) a 10.7 (0.07) a
Endosteal Circumference, mm 6.02 (0.08) a 5.99 (0.11) a 6.01 (0.06) a
Distal Femur mCT
BV/TV,% 42.2 (2.2) a 27.9 (3.2) b 42.3 (1.8) a
Tb.Th, mm 0.112 (0.003) a 0.092 (0.005) b 0.110 (0.003) a
Tb.Sp, mm 0.170 (0.008) a 0.206 (0.011) b 0.171 (0.006) a
Tb.N, # 3.75 (0.13) a 3.02 (0.19) b 3.83 (0.11) a
Conn.Dn, #/mm3 126.9 (6.4) a 116.7 (9.1) a 135.7 (5.3) a
SMI, units 0.50 (0.20) ab 1.32 (0.28) b 0.39 (0.16) a
L4 DXA
aBMD, g/cm2 0.127 (0.004) a 0.125 (0.003) a 0.129 (0.002) a
BMC, g 0.025 (0.002) a 0.024 (0.002) a 0.025 (0.001) a
L4 mCT
BV/TV,% 38.6 (2.5) a 40.7 (2.2) a 42.6 (1.5) a
Tb.Th, mm 0.102 (0.001) a 0.097 (0.002) a 0.102 (0.001) a
Tb.Sp, mm 0.197 (0.008) a 0.197 (0.011) a 0.194 (0.006) a
Tb.N, # 4.04 (0.14) a 4.06 (0.19) a 4.08 (0.11) a
Conn.Dn, #/mm3 97.2 (7.1) a 96.8 (10.0) a 100.4 (5.8) a
SMI, units 0.22 (0.10) a 0.22 (0.14) a 0.18 (0.08) a
aDifferent letters in each row indicate differences among groups by Tukey’s post-hoc comparisons, p,0.05.
doi:10.1371/journal.pone.0108262.t002
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ZDSD rats gain weight with the high fat diet until the onset of
diabetes, after which they begin to lose body weight due to the
catabolic state produced by the diabetes. Indeed, diabetic rats in
the present study had significantly lower body weight at the time of
sacrifice compared with non-diabetic animals, and this may be
associated with their lower BMD.
The results did not show lower bone resorption as measured by
serum CTX in the raloxifene treated rats. However, the
numerically lower BFR/BS and MS/BS with raloxifene treatment
(226% and 227% respectively in RAL versus VEH-ND rats)
supports that the raloxifene treatment had an effect on reducing
bone turnover. The non-significant differences are not surprising
given this study was not powered to detect differences in these
outcomes, and that raloxifene is a relatively weak antiresorptive
agent [25]. However, the magnitude of the difference in BFR/BS
with raloxifene treatment is similar to what we previously observed
in dogs [7]. Additionally, the rats in this study were not
ovariectomized, which also may have reduced our ability to
detect a significant antiresorptive effect of raloxifene. The rats that
became diabetic (VEH-D) had a lower bone formation rate, which
is consistent with reduced bone observed in humans and animals
with diabetes [26]. Despite the lack of significant differences in
bone turnover measures with raloxifene treatment, our results
show that raloxifene improves bone material properties, poten-
tially through direct action of raloxifene on the bone matrix, and
may prevent the induction of diabetes in female ZDSD rats. The
risk of diabetes increases with age [27], as does the risk for bone
fragility fractures [28]. If these results are supported by future
experimental and clinical studies, they suggest that raloxifene
could be a useful drug to prevent skeletal fragility in diabetes with
an added benefit of ameliorating the diabetic condition.
Table 3. Structure-level and material-level mechanical properties of femoral cortical and cancellous bone and L4 cancellous bone
from female ZDSD ratsa.
VEH-ND (n=8)b VEH-D (n=4) RAL (n =12)c
Femur 3-point bending (cortical bone)
Structure-level
Ultimate Force, N 135.1(2.7) a 135.6 (3.6) a 142.7 (2.1) a
Stiffness, N/mm 342.4 (11.1) a 346.8 (14.7) a 342.4 (8.5) a
Energy to Failure, mJ 46.0 (2.9) a 43.7 (3.8) a 57.4 (2.2) b
Post-Yield Energy to Failure, mJ 26.5 (3.0) a 23.5 (4.0) a 36.6 (2.3) b
Post-Yield Displacement, mm 0.210 (0.023) a 0.187 (0.030) a 0.275 (0.017) a
Material-level
Ultimate Stress, MPa 61.4 (1.6) a 61.3 (2.1) a 65.0 (1.2) a
Elastic Modulus, MPa 2683 (92) a 2724 (122) a 2691 (70) a
Toughness, mJ/m3 1.21 (0.08) a 1.13 (0.10) a 1.51 (0.06) b
Post-Yield Toughness, mJ/m3 0.69 (0.07) a 0.61 (0.10) a 0.96 (0.06) b
Distal femur RPC (cancellous bone)b
Structure-level
Ultimate Force, N 21.5 (2.3) a 7.3 (3.1) b 23.7 (1.9) a
Stiffness, N/mm 239.4 (16.8) a 142.6 (22.3) b 249.1 (14.1) a
Energy to Ultimate Force, mJ 1.41 (0.89) ab 0.26 (1.18) a 4.16 (0.75) b
Material-level
Ultimate Stress, MPa 20.6 (2.5) ab 13.6 (3.4) a 27.6 (2.1) b
Modulus, MPa 400.7 (51.6) a 474.5 (68.3) a 534.8 (43.2) a
Toughness, mJ/m3 0.68 (0.55) a 0.25 (0.73) a 2.40 (0.46) a
L4 axial compression (cancellous bone)
Structure-level
Ultimate Force, N 369.9 (18.9) a 317.3 (25.0) a 350.4 (15.1) a
Stiffness, N/mm 1739 (117) a 1476 (155) a 1793 (93) a
Energy to Ultimate Force, mJ 46.6 (3.2) a 40.9 (4.2) a 41.1 (2.5) a
Material-level
Ultimate Stress, MPa 2.27 (0.12) a 2.11 (0.16) a 2.22 (0.10) a
Modulus, MPa 1175 (93) a 1060 (123) a 1269 (74) a
Toughness, mJ/mm3 2.51 (0.13) a 2.28 (0.17) a 2.31 (0.10) a
aDifferent letters in each row indicate differences among groups by Tukey’s post-hoc comparisons, p,0.05.
bn = 7 for VEH-ND for distal femur RPC, L4 axial compression, and femur 3-point bending measures, due to specimens breaking during preparation or unavailable
sample.
cn = 10 for RAL for the distal femur RPC measures and n= 11 for RAL for L4 axial compression measures, due to specimens breaking during preparation.
doi:10.1371/journal.pone.0108262.t003
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